Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

December 31, 2010

Conditions
Recurrent Glioblastoma Multiforme
Interventions
DRUG

Sorafenib and Temozolomide

Temozolomide (50 mg per meter-squared of body surface area)every day by mouth in combination with sorafenib. Sorafenib will be taken by mouth twice every day. The dose of sorafenib will be 400 mg (2 x 200mg tablets).

Trial Locations (1)

27710

Duke University Health System, Durham

Sponsors

Lead Sponsor

Collaborators (2)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

Schering-Plough

INDUSTRY

lead

Duke University

OTHER